2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
8
Recurrence
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
99
Cyclophosphamide
63
fludarabine phosphate
55
Peripheral Blood Stem Cell Transplantation
52
Mycophenolic Acid
34
Whole-Body Irradiation
33
Bortezomib
33
ibrutinib
29
Dexamethasone
27
Tacrolimus
26
Cyclosporine
25
Busulfan
23
Etoposide
22
Melphalan
20
Filgrastim
20
zanubrutinib
18
Methotrexate
18
Lenalidomide
18
Antilymphocyte Serum
18
Radiotherapy
16
Bendamustine Hydrochloride
14
Sirolimus
13
Calcium Dobesilate
11
Flow Cytometry
10
Everolimus
10
venetoclax
9
ibritumomab tiuxetan
9
Prednisone
9
Indium
9
Cyclosporins
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts